KAHR Medical is developing a novel drug platform based on bi-functional, immunotherapeutic fusion proteins, targeting multiple cancer indications
KAHR’s proprietary technology, known as DSP (Dual Signaling Proteins), enables the construction of targeted biological drugs with two functional ends, which can simultaneously block and/or activate two reinforcing biological signals resulting in a synergistic outcome. KAHR’s new...
KAHR Medical is developing a novel drug platform based on bi-functional, immunotherapeutic fusion proteins, targeting multiple cancer indications
KAHR’s proprietary technology, known as DSP (Dual Signaling Proteins), enables the construction of targeted biological drugs with two functional ends, which can simultaneously block and/or activate two reinforcing biological signals resulting in a synergistic outcome. KAHR’s new DSP platform emerged following years of research and development of TNF-superfamily based drug candidates.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.